Skip to main content
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.
Published Web Location
http://europepmc.org/articles/PMC3387495?pdf=renderNo data is associated with this publication.
Abstract
Afatinib is an oral, ErbB family blocker, which covalently binds and irreversibly blocks all kinase-competent ErbB family members. This phase II, open-label, single-arm study explored afatinib activity in human epidermal growth factor receptor 2 (HER2)-pos
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.